The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
'
The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients' 의 참고문헌
Updated guidance for trusted systematic reviews : a new edition of the Cochrane Handbook for Systematic Reviews of Interventions
Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer : pooled analysis of ONO-4538-05 and ONO-4538-06 studies
Safety profile of avelumab in patients with advanced solid tumors : a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer : results of >2 years of follow-up
Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma : a systematic review and meta-analysis
Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma(KEYNOTE-051) : interim analysis of an open-label, single-arm, phase 1-2 trial
Patterns of onset and resolution of immunerelated adverse events of special interest with ipilimumab : detailed safety analysis from a phase 3 trial in patients with advanced melanoma
Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037 : a randomized, controlled, openlabel phase III trial
Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer : twoyear outcomes from two randomized, open-label, phase III trials(CheckMate 017 and CheckMate 057)
Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma : analysis of Japanese patients in CheckMate 214 with extended follow-up
Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation : extended follow-up of the multicohort singlearm phase II CheckMate 205 trial
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy(CA184-043) : a multicentre, randomised, double-blind, phase 3 trial
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3trial
Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma : results from the phase IIIb/IV CheckMate 511 trial
Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma patients who have failed first-line platinum-based chemotherapy
'
The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients'
의 유사주제(
) 논문
